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Summary Con A acceptor glycoproteins from the human Molt 4 (T cell leukaemia) and HeLa (endocervical
adenocarcinoma) cell lines were purified by affinity chromatography and used for the preparation of rat
antisera. Cross-absorption analysis showed that each antiserum contained antibodies which recognised cell
surface antigens preferentially expressed by the donor cell line. Molt 4-associated antigens were fully expressed
on T cell tumour lines and normal thymocytes, but not on non T cell tumour lines, peripheral blood lymphocytes
or other blood cells. Immunofluorescence studies showed that the antigens were preferentially expressed on a
sub-population of immature thymocytes. HeLa-associated antigens were only fully expressed on one other
epithelial tumour cell in a panel of 17 cell lines. Immunofluorescence studies showed that the HeLa-associated
antigens were expressed on normal endocervical adenoepithelium but not on ectocervical, endometrial or
intestinal epithelia. Thus purified Con A acceptor glycoproteins of cultured tumour cell lines are potent
immunogens for the generation of antibodies recognising lineage-associated differentiation antigens. These
antigens should be useful in tumour classification and in the study of normal differentiation.
Two-dimensional gel analysis of the Con A
acceptor glycoproteins of cultured tumour cells has
shown that the complex glycoprotein repertoires
expressed by these cells can be classified into two
general groups; constant glycoproteins which are
expressed by all tumour cells and normal cells of a
species and variable glycoproteins which are only
expressed by some types of cells (Koch & Smith,
1982). Since the patterns of variable glycoproteins
expressed by cells derived from the same pathway
of differentiation are usually similar or even
identical (Koch & Smith, 1983) it was concluded
that the variable glycoproteins reflect the state of
differentiation of the normal precursor cell from
which each tumour cell originates. This linkage of
the pattern of variable glycoproteins to cell
differentiation suggested that they could be of
considerable value as markers for the classification
of tumours as well as the study of normal
differentiation and development. The particular
advantages of the Con A acceptor glycoproteins of
cultured cells are that each cell type can express up
to 50 separate differentiation-linked glycoproteins,
they can be readily isolated in a relatively purified
form by Con A affinity chromatography and large
amounts may therefore be administered to recipient
animals for the preparation of polyclonal and/or
monoclonal antibodies of the desired specificity.
In this study we have assessed the value of the
Con A acceptor glycoproteins of two cultured
human tumour cell lines for the generation of
antibodies which react with antigens preferentially
expressed by the normal cell or tissue from which
each tumour was derived. The results show that the
anti-glycoprotein antibodies do recognise differen-
tiation antigens associated with the tissues of
origin of the respective tumours. Some of these
antigens have the novelty of being preferentially
associated with the relatively immature cells of a
lineage and may therefore provide a systematic
approach to the identification and isolation of the
early cells of a lineage which appear to be the main
source of malignant cells in at least some lineages
(Potter, 1978; Greaves, 1981).
Materials and methods
Reagents
RPMI 1640 was purchased as powdered medium
from Flow Ltd, reconstituted with glass-distilled
water and sterilised by filtration. Penicillin and
streptomycin were obtained as sterile solutions
from Gibco Ltd. Newborn and foetal calf serum
were from Sera-Lab. PBS (2.36 gNa2HPO4;
1.3 gNaH2PO4 2H2O; 8gNaCl pH 7.2 in II)
and EDTA-saline (8gNaCl; 1.15gNa2HPO4;
0.2 gKH2PO4; 0.2 gEDTA pH 7.2 in I1) were
prepared from Analar Chemicals (BDH Ltd) and
sterilised by filtration. CNBr-Sepharose and Con-
canavalin A were from Pharmacia. LymphoprepT
was from Nyegaard, Nonidet P40 from BDH Ltd
and cx-methyl mannoside from Sigma. Rartig was
purchased from Miles Ltd and iodinated by the
Chloramine T method (Hunter & Greenwood, 1962)
with Na 1251 (Amersham 1MS30). Rhodamine and
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fluorescein conjugated antibodies (Miles Ltd) were
passed through a column of Sephadex G25 fine
(Pharmacia) in PBS to remove free fluorochrome
and used at a final dilution of 1:20. Rabbit anti
transferrin receptor antiserum (Bliel & Bretscher,
1982) was a gift from Dr J.D. Bliel and mono-
clonal NA 13/4 antibody (McMichael et al., 1979)
was a gift from Dr C. Milstein.
Cells
HeLa cells were from Dr R.T. Johnson,
Department of Zoology, University of Cambridge;
Molt 4, JM, HPB, CCRF-CEM, Daudi, HMY and
WT52 cells were from Dr C. Milstein, Laboratory
of Molecular Biology, Cambridge; HEp-2, NB100,
HT29, MCF-7, GCCM and GM1063 cells were
from Dr K. Talbot, Ludwig Institute, Cambridge;
RT4, J82, T24 and TCC-Sup cells were from Dr C.
O'Toole, Department of Pathology, University of
Cambridge and LEED cells were from Dr M.
Stanley, Department of Pathology, University of
Cambridge.
Cell lines were grown in RPMI 1640 medium
with 10% newborn or foetal calf serum, 10ml
glutamine, 100Uml-1 penicillin/streptomycin in
Corning tissue culture plastic flasks. Suspension
cells were harvested by centrifugation at lOOg for
5min. Adherent cells were harvested by incubation
at 37°C in EDTA-saline. Human blood cells were
isolated from fresh heparinised blood by
centrifugation on Lymphoprep. The undiluted
blood was layered onto 2vol of Lymphoprep and
centrifuged at 2000g for 20min at 20°C. The
plasma layer was centrifuged at 20,000g for 20min
to obtain a platelet preparation, the interface cells
diluted with PBS pelleted at 2000g to obtain a
lymphocyte preparation and the red cell pellet
washed and used directly. CLL lymphocytes were
obtained from a patient using the above procedure.
All cells were washed with PBS before use in
absorption and binding tests. Viability was always
>90% by the Trypan blue exclusion test.
Thymocytes were obtained from freshly excised
thymus from a patient undergoing paediatric
cardiac surgery. The cells were teased out into PBS
and washed 3 x before use. Cells were stored in
50% foetal calf serum, 10% DMSO in RPMI 1640
medium in liquid nitrogen. Frozen cells were
rapidly thawed and fixed immediately in 3%
formaldehyde in PBS for 15min at room
temperature to prevent fragmentation.
Preparation ofCon A Sepharose
CNBr-Sepharose (Pharmacia) was washed and
swollen as prescribed by the manufacturers. The
swollen resin was coupled to pure concanavalin A
(Pharmacia) using 500mg of Con A per 15ml of
swollen resin. After overnight mixing on rollers the
coupled resin was washed, blocked with 1 M
ethanolamine-HCl pH 8.0 for h at 4°C, washed
and fixed with 0.25% glutaraldehyde in PBS at
room temperature for 15min*. The resin was
washed and resuspended in PBS with azide as
preservative.
Purification ofCon A acceptor glycoproteins
Washed cells were suspended in PBS at a con-
centration of -lOg cells per 50ml of suspension.
Nonidet P40 was then added to a concentration of
2% and after thorough mixing for - 5min on ice
the dense nuclear material was centrifuged out and
the supernatant mixed with 15ml of Con A
Sepharose per 50ml of cell lysate. This was mixed
on rollers for 10-15h at 4°C and the resin washed
5 x with PBS to remove the excess lysate. The
glycoproteins were eluted with 30ml of 20% a-
methyl mannoside in PBS with 2% Nonidet P40 for
1Oh at 4°C. The eluate was dialysed against
10mM Tris pH 7.4 and concentrated by dialysis
against PEG followed by re-dialysis against PBS to
remove excess PEG. The sample was adjusted to a
final concentration of about 5 x 109 cell equivalents
ml-1.
Immunisation with purified Con A acceptor
glycoproteins
2 x 109 cell equivalents (2-4mg protein for Molt 4
and HeLa glycoproteins) in 600pl of PBS were
mixed with 600 4ul of Freunds complete adjuvant
and injected intraperitoneally into AO x Lou strain
rats. After 1 month a similar injection was carried
out and test bleeds obtained after a further 2 weeks.
Standard binding assayfor antibodies to cells
Cells (2 x IO1) were incubated with rat antiserum
(total volume 100 pl) in microtite plates for h at
20°C. The cells were washed 3 times and incubated
with 50pl of 1251I-Rartig (106c.p.m.ml-1) for th at
20°C. After washing, cells were counted in an LKB
multi-gamma counter.
For antiserum titrations, antisera were serially
diluted starting at a 1:1000 dilution. In the
absorption test (see below), absorbed antisera were
assayed as above using an antiserum dilution
equivalent to 50% of maximal binding to the
homologous cell line (i.e. anti-Molt with Molt 4
cells and anti-HeLa with HeLa cells). Pre-bleed sera
*Fixation of ConA was carried out to reduce leaching to
the lectin from the resin during elution of glycoproteins to
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were used as control for non-specific binding. All
dilutions and washings were carried out in dilution
medium (PBS, 10% foetal calf serum, 0.02% sodium
azide).
Standard absorption assayfor antigen expression
Each cell line was serially diluted starting at 2 x 107
HeLa cell equivalents (see below) and mixed with
anti-serum (anti-Molt 4 or anti-HeLa glycoproteins
at 1:50,000 or 1:10,000 dilution respectively) in a
final volume of 200M1 in Luckham LP3 tubes. After
incubation on a rolling mixer for 2h at 40C, the
cells were spun out and the residual antibody
activity measured in the standard binding assay.
The measure of antigen expression was the
maximum absorption (%) achievable by each cell
line. Therefore it was necessary to use a starting
concentration of cells which was sufficient to
ensure a plateau level in the absorption curve for
each cell line. Preliminary studies showed that by
using a starting cell pellet equivalent in volume to
2 x 107 HeLa cell equivalents the achievement of
the maximum absorption was ensured.
It should be emphasised that because the residual
activity represents antibodies directed against
antigens completely absent from the test cell line
the measure of antigen expression (maximum
absorption) for each cell line is independent of
cell volume, surface area or antigen density. This
assay also permits the comparison of antigen
expression between cells and acellular material such
as tissue extracts, membranes, etc.
Preparation ofspleen membranesfor absorption
Frozen human spleen was thawed and minced with
scissors to yield a coarse suspension in 3 volumes
of ice-cold PBS. The suspension was dispersed in
a Polytron homogeniser and the dense material
removed by centrifugation at 1000g. Membranes
were collected by centrifugation at 100,OOOg for
1 h onto a cushion of 45% sucrose in PBS. The
membranes were diluted and pelletted at 100,OOOg
for 1 h to produce a stock suspension. After use in
the absorption tests membranes were removed by
pelletting at 100,OOOg for 1 h.
Immunofluorescence
Molt 4 and the HeLa glycoprotein antisera (1: 100
in dilution medium) were absorbed with human
spleen membranes and HT29 colon carcinoma cells
respectively to remove antibodies reacting with
common antigens. Absorbed Molt 4 glycoprotein
antiserum was used at a dilution of 1:200 or
1:1000 and absorbed HeLa glycoprotein antiserum
at a dilution of 1: 1000. NA13/4 antibody was from
a culture supernatant and was used undiluted.
Rabbit anti-human transferrin receptor serum was
diluted 1:100 in dilution medium. Thymocytes or
cryostat sections were fixed with formaldehyde as
described by Finan et al. (1982) before use. After
incubation for 1 h at 20°C with the first antibody,
and washing 3 times with dilution medium, samples
were incubated with the fluorescent antibody for 1 h
at 20°C, washed 3 times with dilution medium,
mounted in 50% glycerol in PBS and examined for
epifluorescence on a Zeiss microscope. Rat anti-
bodies were developed with Rh-Rartig (1:20)
NA13/4 anti-body with Fl-Ramig (1:20) and
Rabbit anti-transferrin receptor with Fl-Garig
(1:20). For double labelling experiments on
thymocytes, the anti-transferrin receptor antibody
was used first, blocked with neat rabbit serum
for 30min at 20°C, followed by the rat/anti-rat
antibodies. Fluorescent rabbit anti-rat and anti-
mouse antibodies showed no cross-reaction and
could be used in any sequence. Cryostat sections of
human ectocervix, endocervix and endometrium were
kindly provided by Dr M. Stanley and sections
of human intestinal epithelia were kindly provided
by Dr P. Ciclitira. They were stained according to
the procedure described by Finan et al. (1982).
Gel electrophoresis
SDS gel electrophoresis was carried out according
to the method of Laemmli (1970) and stained for
protein with Coomassie Blue. 2D-gel analysis with
1251 Con A was carried out as described previously
(Koch & Smith, 1982).
Estimation ofprotein
Protein was measured by the Coomassie Blue
procedure using bovine serum albumin as standard
(Bradford, 1976).
Results
Isolation ofCon A acceptor glycoproteinsfor
immunisation
Figure 1 shows the composition of purified glyco-
protein preparations from the HeLa and Molt 4
cell lines. When SDS gel electrophoresis is used for
analysis a few major bands are observed with the
conventional protein stain. However, when analy-
sed by 2D gel electrophoresis in conjunction with
121I Con A overlay it is clear that the preparations
contain a large number of Con A binding com-
ponents. Thus although these preparations are
relatively enriched for the Con A acceptor glyco-
proteins they are still quite complex mixtures of
glycoproteins.16 G.L.E. KOCH & M.J. SMITH
anti Molt 4/Molt 4 Targets
100
60
20
100
m
Molt 4 ABS
HeLa ABS
9
100 25 6.2 1.5
anti HeLa/HeLa Targets
60
20
Figure 1 Composition of purified Con A acceptor
glycoproteins from cultured tumour cell lines. (A)
Eluates from Con A Sepharose analysed by SDS gel
electrophoresis, and stained for protein with
Coomassie Blue. (1) Protein standards (glycogen
phosphorylase 95 kD, bovine serum albumin 65kD,
ovalbumin 45kD, carbonic anhydrase 30kD). (2)
Glycoproteins from Molt 4 cells. (3) Glycoproteins
from HeLa cells. (B) HeLa glycoproteins analysed by
2D gel and 125I Con A overlay (Koch & Smith, 1982).
(C) Molt 4 glycoproteins analysed by 2D gel and 125I
Con A overlay.
Antibodies to Molt 4 and HeLa glycoproteins
recognise cell surface antigens preferentially
expressed by the donor cell line
Rats immunised with purified glycoproteins from
either the Molt 4 or HeLa cell lines produce high
levels of antibodies which react with surface
antigens from the donor cell line. In some animals
the binding titres of these antisera exceed 3 x 105
showing that the soluble glycoproteins are potent
immunogens. Figure 2 shows that whereas Molt 4
cells could completely absorb out the antigens
recognised by the anti-Molt 4 glycoprotein anti-
bodies, the HeLa cell could only absorb out -20%
of the activity in the same test system. In the
reciprocal experiment using the antibodies to the
HeLa cell glycoproteins, Molt 4 cells could only
absorb -20% of the anti-HeLa antibodies.
Molt 4 - associated glycoprotein antigens are
expressed on T-ALL cell lines and normal
thymocytes
The expression of the antigens recognised by the
antibodies to the Molt 4 glycoproteins was
100 25 6.2 1.5
Cell no. (x 10-5)
Figure 2 Detection of specific antibodies in antisera
to Molt 4 and HeLa glycoproteins. Anti-Molt 4
glycoprotein serum (dil 1:50,000) and anti-HeLa
glycoprotein serum (1:10,000) were absorbed with
varying amounts of Molt 4 and HeLa cells in the
standard absorption assay. Absorbed samples were
tested for binding to Molt 4 and HeLa cells
respectively. Top. Absorption of anti-Molt 4 by Molt
4 and HeLa cells. Bottom. Absorption of anti-HeLa
by Molt 4 and HeLa cells.
examined by absorption analysis with a panel of
cell lines and normal cells. In each case the
maximum possible absorption was determined by
titration (see Figure 2) with adequate amounts
of the test sample in the anti-Molt 4/Molt 4 test
system. Table I shows that the maximum absorption
achieved by the non-T cell lines was 35% of the
total anti-Molt 4 activity. This probably represents
the activity towards common antigens in the anti-
Molt 4 serum. In contrast, all the T cell tumour
lines absorbed the anti-Molt 4 activity completely,
indicating that they expressed all the antigens
recognised by the serum.
Analysis of normal cells and tissues also indi-
cated that the antigens recognised by the anti-
Molt 4 serum were normal differentiation antigens
associated with the T cell lineage. Thus, platelets,
erythrocytes, peripheral lymphocytes and spleen
membranes failed to absorb >50% of the total
activity. In contrast the absorption by thymocytes
was complete. When the Molt 4 glycoprotein
anti-serum was absorbed by spleen membranes, the
I
cn
coANTIBODIES TO TUMOUR CELL GLYCOPROTEINS 17
Table I Expression of Molt 4 glycoprotein antigens by cultured tumour cells,
normal cells and tissues.
% Absorption of
Cell Ref Cell type Molt 4 antibodies
Molt 4 a T-cell leukaemia 100
JM a T-cell leukaemia 100
HPB a T-cell leukaemia 100
CCRF-CEM b T-cell leukaemia 100
Daudi c B-cell leukaemia 36
Hmy d B-cell leukaemia 25
HeLa e Endocervical carcinoma 15
HEp-2 f Laryngeal carcinoma 15
LEED g Cervical squamous carcinoma 33
RT4 h Bladder TC carcinoma 32
NBIOO i Neuroblastoma 34
Erythrocytes 15
Platelets 30
Peripheral blood lymphocytes 37
CLL-lymphocytes 45
Spleen membranes 35
Thymocytes 100
Anti-Molt 4 glycoprotein antibodies were completely absorbed by each test cell as
described in Materials and methods and residual activity tested with Molt 4 cells in
the standard binding assay.
aMinowada (1980); bFoley et al. (1965); cKlein et al. (1968); dEdwards et al.
(unpublished); eGey et al. (1952); fToolan (1954); gNot available; hRigby & Franks
(1970); 'Not available.
residual antibodies bound strongly to thymocytes
but weakly to peripheral blood lymphocytes
(Figure 3).
Studies with monoclonal antibodies have shown
that human thymocytes express a major antigen
HTA (McMichael et al., 1979) which is not
expressed on mature T cells. Several observations
showed that the thymocyte antigens recognised by
the anti-Molt 4 serum were not HTA. Double
immunofluorescence studies on normal thymocytes
with anti-HTA and anti-Molt 4 antibodies reveal
clear differences between their pattern of expression
(Figure 4). First, the HTA and Molt 4 antigens are
not expressed on the same sub-population of cells.
In fact, cells which are high in HTA are usually
low in the Molt 4 antigens and vice versa (Figure
4C,D). When the two sets of antigens are expressed
by the same cell the pattern of expression is also
different. The HTA usually gives a regular punctuate
pattern over the whole cell surface whereas the
pattern of the Molt 4 antigens is more uniform and
distinct from the HTA pattern. Thus it appears that
the Molt 4 antigens are distinct from the human
thymocyte antigen.
Evidence was also obtained that some of the
Molt 4 antigens are preferentially expressed on the
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Figure 3 Specificity of anti-Molt 4 glycoprotein
antibodies after absorption with spleen membranes.
Crude human spleen membranes were prepared as
described in Materials and methods, titrated for
maximum absorption and the fully absorbed serum
tested for binding to human thymocytes (THY) and
peripheral blood lymphocytes (PBL) in the standard
binding assay. Thymocytes and lymphocytes were fixed
with formaldehyde as described in Materials and
methods.18 G.L.E. KOCH & M.J. SMITH
Figure 4 Immunofluorescence labelling of human
thymocytes with anti-Molt 4 glycoprotein antibody.
Anti-Molt 4 glycoprotein serum (dil 1: 100) was
absorbed once with spleen membranes and used for
immunofluorescence with fixed thymocytes as
described in Materials and methods. (A) Cells labelled
with absorbed antibody at 1:200 final dilution. (B)
Cells labelled with absorbed antibody at 1:1000 final
dilution. (C,D) Cells labelled with NA134 (anti-HTA
monoclonal antibody) +Fl-Ramig followed by
absorbed anti-Molt 4 glycoprotein antibody
(1:200)+Rh-Rartig. Arrows show the same cells in
the two fields (C) Fl-label; (D) Rh-label. (E,F) Cells
labelled with rabbit anti-transferrin receptor
antibody +FITC-Garig, blocked with normal rabbit
serum followed by absorbed anti-Molt 4 glycoprotein
serum (1: 1000) +Rh-Rartig. (E) FITC label; (F) Rh
label.
very immature thymic blast cells. When thymocytes
were stained with relatively high dilutions of
antibody the general staining was decreased but a
sub-population of cells still showed strong staining
(Figure 4B). These cells usually had an irregular
outline and were amongst the largest cells in
the thymocyte preparations. Double immuno-
fluorescence with anti-transferrin receptor antibody
and anti-Molt 4 antibody showed that these were
also the cells which expressed the highest levels of
the transferrin receptor (Figure 4E,F). Since high
expression of the transferrin receptor is associated
with the immature thymic blast cells (Greaves,
1981; Reinharz & Schlossmann, 1981) these obser-
vations suggest that the Molt 4 antigens are also
preferentially expressed by the immature thymic
blasts.
Antibodies to HeLa glycoproteins recognise antigens
expressedpreferentially by HeLa cells and normal
endocervical epithelium
The antibodies to the HeLa glycoproteins were
examined by absorption analysis with a panel of
cultured tumour cell lines (Table II). Absorption by
lymphoblastoid cell lines did not exceed -.40%.
Other cell lines from various epithelial tissues
showed somewhat higher levels of absorption i.e.
up to 75%. When the HeLa glycoprotein anti-
serum was completely absorbed with one cell line
(HT29) and then re-absorbed with four other cell
lines (Molt 4, LEED, RT4 and NB100) no additional
absorption occurred, indicating that absorption
is not generally additive. Only one cell line
examined so far was able to absorb out all the
anti-HeLa activity i.e. the laryngeal carcinoma line
Hep2. These studies indicated that a significant
proportion of the antibodies to HeLa glycoproteins
recognised antigens preferentially expressed on the
HeLa cell line.
In order to determine whether the HeLa-
associated antigens were expressed by cells of the
endocervical epithelium, the putative tissue of
origin of the HeLa cell (Jones et al., 1970) cryostat
sections were examined by immunofluorescence
staining with the anti-HeLa serum after absorption
with the HT29 cell line to remove antibodies to
common epithelial antigens. Figure 5 shows
sections through the endocervical glands which
exhibit a characteristic punctate pattern of staining
associated with the outer membranes of epithelial
cells.
The specificity of the staining for the endo-
cervical epithelium was examined by immuno-
fluorescence with cryostat sections from ectocervical,
endometrial and intestinal epithelia. In all cases
the staining was not significant. When the pre-
immune serum or antiserum absorbed with HeLa
cells was used the staining of the endocervical cells
was abolished (unpublished observations). Thus
the HeLa-associated antigens are preferentially
expressed by the cells of the endocervical epithelium.ANTIBODIES TO TUMOUR CELL GLYCOPROTEINS 19
Table II Expression of HeLa glycoprotein antigens by cultured tumour cells.
Maximum absorption (%)
Cell Ref Type ofanti HeLa GP serum
HeLa a Adenocarcinoma, cervix 100
LEED b Squamous carcinoma, cervix 16
HT29 c Adenocarcinoma, colon 45
HEP2 d Carcinoma, larynx 100
MCF7 e Carcinoma, breast 16
RT4 f Transitional cell carcinoma, bladder 15
J82 g Transitional cell carcinoma, bladder 68
T24 h Transitional cell carcinoma, bladder 55
TCC Sup i Transitional cell carcinoma, bladder 75
Molt 4 j T cell leukaemia 25
Hmy k B cell leukaemia 12
Daudi 1 Burkitts lymphoma 12
WT52 m B cell leukaemia 42
GCCM n Glioma 63
GM1063 o Fibroblast 55
Willis p Fibroblast 66
NB100 q Neuroblastoma 30
Anti-HeLa glycoprotein antibodies were completely absorbed by each test material
as described in Materials and methods and residual activity tested with HeLa cells in
the standard binding assay.
aGey et al. (1952); bNot available; cFogh et al. (1977); dToulan (1954); eSoule et al.
(1973); 'Rigby & Franks (1970); "O'Toole et al. (1978); hBubenik et al. (1970); 'Nayak
et al. (1979); iMinowada (1980); 'Edwards et al. (unpublished); 'Klein et al. (1968);
mNot available; 'Garson et al. (1981); °Nyhan et al. (1970); PNot available; qNot
available.
Discussion
These studies show that purified Con A acceptor
glycoproteins of cultured tumour cell lines are
potent immunogens for the production of anti-
bodies with a substantial specificity towards the
immunising cell line. A major contributing factor
to this is the use of large amounts of purified
glycoproteins from cultured cell lines as immuno-
gens. The need to use up to 10g of tumour cell
equivalents in such immunisations was suggested by
the preliminary studies which showed that ig
quantities ofa soluble antigen like chicken ovalbumin
were required to generate a satisfactory antibody,
and that the 'specific' glycoproteins expressed by
the cultured tumour lines are very minor com-
ponents of such cells. This illustrates one of the
advantages ofusing suitably characterised molecules
as immunogens since it can reduce at least some of
the uncertainty involved in all such immunisations.
It also emphasises the value of using purified
immunogens since adequate amounts of minor com-
ponents can be administered during immunisation.
The main object of these studies was to examine
the specificity of the antibodies obtained when
purified Con A acceptor glycoproteins were used as
immunogens. It is clear that such antibodies show
significant specificity towards antigens expressed by
the donor cell line. Thus in the Molt 4/HeLa cross-
comparison -80% of the antibodies which react
with the donor cell line fail to react with the other
line (Figure 1). In the more general comparisons
with unrelated cultured tumour cell lines the non-
specific reactivity is usually around -50% (Tables
I and II). Thus it is possible to produce an anti-
serum of high titre and specificity towards the
donor cell line by a single absorption with an
unrelated line.
The antigens which are preferentially expressed
by the Molt 4 cell line are also fully expressed on
other cell lines of the T cell lineage. The implication
of this linkage to tumour cells derived from a
specific lineage is that the antigens are differen-
tiation markers associated with T cell development.
This was directly confirmed by the observation that
the antigens are fully expressed on normal human20 G.L.E. KOCH & M.J. SMITH
Figure 5 Expression of HeLa-associated glycoprotein
antigens on human endocervical epithelium. (A) Anti-
HeLa glycoprotein antibody (1:100 dil) was absorbed
once with HT29 cells to completely remove antibodies
reacting with common antigens. Cryostat sections were
stained as described by Finan et al. (1982) using Rh-
Rartig as second layer. Sections through normal
endocervical glandular ducts are shown. Control (pre-
immune and HeLa-absorbed) sera showed no staining
of parallel sections.
thymocytes, the immature precursors of T cells.
Similarly, the HeLa-associated antigens were found
on normal endocervical epithelium, the putative
tissue of origin of the HeLa cell but not on the
other epithelial tissues examined. The main excep-
tions to this specificity for cells of the same lineage
as the donor cell is the HEp-2 cell line which is
derived from laryngeal epithelium (Toolan, 1954)
but expressed all the antigens recognised by the
anti-HeLa antibodies. This similarity in the antigen
profiles of the HEp-2 and HeLa cell lines could
reflect the properties of the normal epithelial cells
from which they originated. However, it has been
shown that HEp-2 cells from a number of sources
(including the ATCC collection) express the specific
markers such as the marker chromosomes, G6PD
type A isozyme and lack of Y chromosome
associated with the HeLa cell line (Nelson-Rees
et al., 1981). Thus the similarity in the antigen
profiles of HEp-2 and HeLa may reflect this
putative contamination rather than the properties
of authentic laryngeal carcinoma cells. It is worth
noting that in view of the numerous reports of
HeLa contamination of cell lines, the simple
absorption test using the anti-HeLa glycoprotein
serum used in these studies could provide a rapid
screening assay for HeLa cell contamination in
laboratory cultures.
It is interesting that there is no evidence in these
studies for antigens which are not expressed by the
normal cells from which the tumour cells arise.
Thus thymocytes fully express all the antigens
detected by the anti-Molt 4 antibodies. It is
remarkable that the HeLa cell line which has been
in cell culture for several decades (Gey et al., 1952)
under poorly controlled conditions should retain the
glycoprotein antigen profile of the normal tissue
from which it was derived. However these obser-
vations are consistent with previous studies showing
that the glycoprotein fingerprints ofcultured tumour
cells do not change during long-term tissue culture
(Koch et al., 1983). This suggests a general
approach to the classification of tumour cell lines
where there is an uncertainty about their origin i.e.:
anti-glycoprotein antibodies can be prepared,
absorbed till they are specific towards the donor cell
line, and then used to examine antigen expression
on prospective normal tissues.
The absence of most of the Molt 4-associated
antigens on mature T cells shows that they are
preferentially expressed on the relatively immature
cells of the T cell lineage. This is not surprising
since it is well-established that T-ALL is associated
with the proliferation of cells in the thymus
(Reinherz & Schlossman, 1981). However the
indications that the Molt 4-associated antigens are
preferentially expressed by the very immature
thymic-blast cells is more interesting since there
are no known markers which are both T lineage
specific and preferentially expressed by the cells at
the earliest stages of commitment to this lineage.
Such markers could be particularly valuable in the
isolation and characterisation of pure populations
of prothymocytes.
Although purified preparations enriched for the
specific glycoproteins were used as immunogens, it
has not yet been directly demonstrated that these
are the antigens actually recognised by the specific
antibodies. The immunochemical analysis required
for such studies were precluded by the limited
amounts of rat anti-serum available. The use of ratsANTIBODIES TO TUMOUR CELL GLYCOPROTEINS 21
rather than larger species such as rabbit or sheep
was dictated by the intention to go on to the
production of monoclonal antibodies if the anti-
glycoprotein sera proved promising. It also remains
to be determined to what extent the protein and
carbohydrate moieties of the glycoprotein immuno-
gens contribute to the specificity of the antibodies.
Studies with monoclonal antibodies to tumour cells
surfaces have led to the suggestion that the dif-
ferentiation antigens expressed on cell surfaces are
predominantly carbohydrate moieties (Feizi, 1985).
However it has not been excluded that this selectiv-
ity for carbohydrate antigens is a reflection of the
approaches used in the production of monoclonal
antibodies (Feizi, 1985) and not necessarily a
reflection of the absence of protein antigens
generally. A detailed analysis of the biochemical
nature of the antigens recognised by the specific
antibodies in the anti-glycoprotein sera could be
instructive.
The main outcome of these studies is that they
suggest a general approach to the identification of
lineage-associated differentiation antigens. It relies on
the use of a pure cultured tumour cell population
as the source of a purified set of immunogens which
can be shown by independent biochemical analyses
to be expressed in a lineage-associated fashion. It
is expected that by combining these well defined
immunogens with the hybridoma technique (Kohler
& Milstein, 1975) novel markers for tumour
classification and cell differentiation can be
identified in a reliable and predictable approach.
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